Resources
The National Pharmaceutical Council (NPC) is a health policy research organization dedicated to the advancement of good evidence and science, and to fostering an environment in the United States that supports medical innovation.
Filter by:
Topic
Topic
- Accountable Care Organizations
- Alternative Payment Models
- Biopharmaceutical Innovation
- Bundled Payments
- Clinical Pathways
- Decision Frameworks
- Elements of Value
- Evidence for Decision Making
- Formulary Development
- (-) Good Practices for Evidence
- Health Care Quality Measures
- Health Spending
- Health Spend Management
- (-) High-Deductible Health Plans
- Impact on Outcome & Spending
- Individual Treatment Effects & Personalized Access
- Low-Value Care
- NPC News
- Pandemic Response
- Patient Centered Formulary & Benefit Design
- (-) Patient Cost Sharing
- Paying for Cures
- Policy & Regulatory Barriers
- (-) Real-World Data
- Real-World Evidence
- Regulatory Barriers & Challenges
- Understanding Health Spending
- Utilization Management & Step Therapy
- Value-Based Contracts
- (-) Value-Based Insurance Design
- Value Assessment
- Value Assessment Frameworks
- Value Assessment Methods
Resource Type
Resource Type
Display Only
Showing 55 Results
Skyrocketing Deductibles Should Be a Focus of Open-Enrollment Season
The dizzyingly complex process of shopping for health insurance can obscure some of the most important factors in making a choice.
Characterizing health plan evidence review practices: how often, how different, and how comprehensive?
All health care decisions should be evidence-based. Until now, it has been relatively unclear what goes into health plan evidence reviews. How frequently do health plans update their specialty drug…
Predictors of Adherence to Oral Anticancer Medications: An Analysis of 2010-2018 U.S. Nationwide Claims
Low-income Medicare patients who face high out-of-pocket costs are less likely to remain adherent to oral anticancer medications. This research shows the need for strategies to address adherence and…
Premium Impact of Expanding Pre-Deductible Coverage to Chronic Disease Management Medications in HSA-Eligible Health Plans
An NPC-funded study found the impact on premiums of expanding pre-deductible coverage to 116 drug classes related to chronic disease management medications in HSA-eligible health plans is small …
Specialty Drug and Healthcare Utilization Vary by Wage Level in Employer-Sponsored Health Plans
This research shows that low-wage employees are less likely use autoimmune medicines than employees who earn more despite a higher prevalence of autoimmune conditions in low-wage employees. These…
The Impact of Expanding Pre-Deductible Coverage in HSA-Eligible Health Plans on Premiums
Research found that expanding pre-deductible coverage under employer-led health plans would add few costs to health insurance premiums, while lowering costs for patients.
Expanding Pre-Deductible Coverage in HSA-Eligible Health Plans Benefits Patients
Expanding pre-deductible coverage under employer-led health plans would add few costs to health insurance premiums, according to a research report by the Employer Benefits Research Institute.
Pharmacists Can Help the Pharmaceutical Ecosystem Work Better for Patients
In a commentary, NPC President and CEO John O’Brien reflects on his personal experience as a pharmacist and how that training led him on the path to a career in health policy.
Cost-Sharing and Adherence, Clinical Outcomes, Health Care Utilization, and Costs: A Systematic Literature Review
Higher patient cost-sharing for prescription medications leads to worse medication initiation, adherence, persistence, and discontinuation, according to a new systematic literature review by…
High Patient Out-of-Pocket Costs Lead to Worse Medication Adherence Without Overall Health Care Savings
Research from NPC and Xcenda suggests that high cost-sharing for prescription medications may have negative effects on patient health while not actually decreasing overall health care costs.
Why Patients Are Paying More at the Pharmacy Counter in Early 2022 - And What We Can Do to Fix It
NPC Immediate Past Board Chair Mike Ryan and CSO Sharon Phares explore policy solutions to ensure patients can have predictable and affordable out-of-pocket costs for medicines.
High-Deductible Health Plans: Good Practices for Employers
Research highlights good practices for designing high-deductible health plans to help enrollees better maximize the value of their benefits.
Employers Identify Good Practices for High-Deductible Health Plans
Employers can design a smarter high-deductible health plans by following good practices identified in NPC research.
Drug Price Controls in Medicare Part D: Not a Remedy for More Than 5 Million Medicare Beneficiaries
Proposals seeking to improve access for Medicare beneficiaries should ensure that patients are better able to get the medicines their doctors say they need.
Kimberly Westrich Talks Benefit Design with AJMC
NPC's Vice President of Health Services Research, Kimberly Westrich, MA, discusses how the healthcare system can incentivize high-value care.
Better Value, Smarter Deductibles in HSA-HDHPs: Improving Health, Equity & Engagement
NPC and National Alliance of Healthcare Purchaser Coalitions collaborated on an Action Brief highlighting key steps employers can take to enhance their health benefit design approach.
Employers Embrace Opportunity to Increase Patient Access to Preventive Care for Chronic Conditions Through Pre-Deductible Coverage
Expanding pre-deductible health coverage for HSA-eligible plans could benefit millions of Americans suffering from chronic conditions as well as lower health care costs by reducing barriers to…
Employer Uptake of Pre-Deductible Coverage for Preventive Services in HSA-Eligible Health Plans
An NPC-funded study shows many large employers have expanded pre-deductible coverage for medications and health services used to prevent exacerbations of common chronic conditions and would like to…
The Impact of COVID-19 on Real-World Health Data and Research
This white paper provides key health care stakeholders, including clinicians, researchers, payers and regulators, with a broad view of how the COVID-19 pandemic may have impacted real-world data (RWD…